Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) has provided an update on its ongoing non-brokered private placement offering of up to 20,000,000 units priced at $0.15 each, targeting gross proceeds of up to $3,000,000. The Calgary-based biotechnology company intends to use net proceeds primarily to fund a deposit for phase 1 clinical trials of its lead compound MB-204, alongside general and administrative expenses and working capital. The first tranche is now expected to close on or about September 30, 2026, following a TSXV-approved deadline extension.

Key Points

  • Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) is a Calgary-based pre-clinical stage pharmaceutical development company
  • Non-brokered private placement of units priced at $0.15 each, with a minimum of 10,000,000 units ($1,500,000) and a maximum of 20,000,000 units ($3,000,000)
  • Each unit comprises one common share and one warrant exercisable at $0.20 per share for one year from closing, with an acceleration clause if the 5-day VWAP reaches $0.25
  • Investors will be watching for TSXV regulatory approval and successful closing on or about September 30, 2026

Unit Structure and Warrant Acceleration Terms for the MRVL Offering

Each unit sold in the offering consists of one common share and one common share purchase warrant. Warrants become exercisable at $0.20 per share beginning on the 61st day after closing and remain valid for one year from the closing date. The company retains the right to accelerate warrant expiry if the volume weighted average trading price of common shares on the TSXV reaches at least $0.25 for five consecutive trading days, provided holders receive no less than 30 days' notice, which may be delivered via press release.

MB-204 Phase 1 Trial Deposit Among Planned Uses for Offering Proceeds

The announcement states that net proceeds are intended to pay a deposit for phase 1 clinical trials for MB-204, the company's lead compound, in addition to general and administrative expenses and working capital. MB-204 falls within Marvel's drug redevelopment strategy, which focuses on developing synthetic chemical derivatives of known, off-patent drugs. The company's pipeline includes compounds targeting the A2a adenosine receptor, with applications in neurological conditions such as depression, anxiety, Alzheimer's disease, and ADHD, as well as cancer and non-alcoholic steatohepatitis.

Finder's Fee Terms and TSXV Deadline Extension Details

In connection with the offering, Marvel will pay finders a cash fee of up to 7% of gross proceeds raised through their introductions, plus finder's warrants equal to 7% of the aggregate units attributed to their subscribers. The company estimates up to 700,000 common shares could be issued on exercise of finder's warrants at minimum offering size, rising to 1,400,000 at maximum. The TSXV approved an extension of the deadline to file final closing materials from September 14, 2026 to September 30, 2026. Closing remains subject to all required regulatory approvals.